Prevelance of drug drug interactions in hospitalized patients with concomittent cardiovascular disease and COVID-19

Abstract

Drugs interact with other drugs, foods, beverages and herbs; outside or inside the body. Drug interaction is an alteration in the nature or effect of drugs due to concurrent administration of one or more drugs, foods or beverages. Concomitant medical conditions and multiple drug treatment regimens play an essential role in the incidence of drug-drug interactions (DDIs). DDIs are considered one of the important part of adverse drug events that results in adverse drug reactions (ADRs). Aim: To evaluate DDIs rate among hospitalized patients with cardiovascular disease who were diagnosed with COVID-19 in Shahid Madani Cardiovascular hospital. Methods: This study was conducted during a 12-month period on 151 patients with cardiovascular disease and COVID-19. In the questionnaire-Based research, patients' demographic, medical and drug history, and social and habitual history were recorded. DDIs were evaluated based on Lexicomp software, then data was analyzed using SPSS. Results: The mean ±SD of patients' age was 65.85 ± 12.87. The most of patients had at least one DDIs (93.4%). A total of 1581 cases of DDIs were recorded. Of which 23 were class X, need to avoid, 209 were class D, need to consider to change, re-dosing or continuous monitoring and 1349 were class C that needs monitoring and dose adjustment in high-risk patient may be necessary. Conclusion: In this investigation the most detected DDIs were considered as class C that needed therapy-monitoring.It is recommended to monitor the incidence of DDIs among hospitalized patients with cardiovascular disease with confirmed COVID-19.